AR051512A1 - Proteina de fusion que comprende un dominio bh3 de una proteina "solo bh3" - Google Patents
Proteina de fusion que comprende un dominio bh3 de una proteina "solo bh3"Info
- Publication number
- AR051512A1 AR051512A1 ARP050104939A ARP050104939A AR051512A1 AR 051512 A1 AR051512 A1 AR 051512A1 AR P050104939 A ARP050104939 A AR P050104939A AR P050104939 A ARP050104939 A AR P050104939A AR 051512 A1 AR051512 A1 AR 051512A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- fusion protein
- domain
- solo
- refers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a una proteína de fusion que incluye como mínimo una primera porcion (I) que comprende una secuencia de tráfico y como mínimo una segunda porcion (II) que comprende una secuencia de dominio BH3 parcial o de longitud completa de una proteína ôsolo BH3ö, comprendiendo dicha proteína de fusion aminoácidos D-enantioméricos en orden retro-inverso en su porcion (I). Además, la presente se refiere a composiciones farmacéuticas que contienen dicha proteína de fusion y también al uso de dicha proteína de fusion.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04028278A EP1661912A1 (en) | 2004-11-29 | 2004-11-29 | Fusion protein comprising a BH3-domain of a BH3-only protein |
Publications (1)
Publication Number | Publication Date |
---|---|
AR051512A1 true AR051512A1 (es) | 2007-01-17 |
Family
ID=34927574
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050104939A AR051512A1 (es) | 2004-11-29 | 2005-11-25 | Proteina de fusion que comprende un dominio bh3 de una proteina "solo bh3" |
Country Status (11)
Country | Link |
---|---|
US (1) | US20080274956A1 (es) |
EP (2) | EP1661912A1 (es) |
JP (1) | JP2008521759A (es) |
CN (1) | CN101068832A (es) |
AR (1) | AR051512A1 (es) |
AU (1) | AU2005308990A1 (es) |
BR (1) | BRPI0516659A (es) |
CA (1) | CA2590512A1 (es) |
EA (1) | EA013469B1 (es) |
IL (1) | IL182460A0 (es) |
WO (1) | WO2006056370A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
CA3031270A1 (en) | 2004-03-03 | 2005-12-22 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
US20070065421A1 (en) * | 2005-09-16 | 2007-03-22 | Firestein Gary S | Inducing expression of puma to reduce joint inflammation in the treatment of arthritis |
US7582606B2 (en) * | 2005-11-03 | 2009-09-01 | The Board Of Regents Of The University Of Texas System | Nadph oxidase cytosolic cofactor mutant |
AU2007340162B2 (en) * | 2006-12-29 | 2013-08-01 | Revance Therapeutics, Inc. | Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT |
AU2007340158A1 (en) * | 2006-12-29 | 2008-07-10 | Revance Therapeutics, Inc. | Transport molecules using reverse sequence HIV-TAT polypeptides |
US8785388B2 (en) * | 2007-02-14 | 2014-07-22 | Saint Louis University | TAT-BH3 methods for treating arthritis |
EP2178549B1 (en) | 2007-07-26 | 2016-09-14 | Revance Therapeutics, Inc. | Antimicrobial peptide and compositions thereof |
CN101580548B (zh) * | 2008-05-12 | 2013-06-05 | 中国医学科学院肿瘤研究所 | 抑制肿瘤生长的融合肽及其在制备抗肿瘤药物中的用途 |
WO2012048721A1 (en) | 2010-10-14 | 2012-04-19 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
SG182016A1 (en) * | 2010-12-14 | 2012-07-30 | Univ Singapore | Method of detecting resistance to cancer therapy |
WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
US20140120077A1 (en) | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and Methods for Safe Treatment of Rhinitis |
JP2016530232A (ja) | 2013-06-24 | 2016-09-29 | ミルナ セラピューティクス,インク. | Mir−34活性のバイオマーカー |
AU2014301631A1 (en) | 2013-06-26 | 2015-08-27 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases |
WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
KR101818809B1 (ko) * | 2014-07-24 | 2018-02-21 | 가톨릭대학교 산학협력단 | Bad 발현 촉진제를 포함하는 엡스타인-바 바이러스 감염증 치료용 조성물 |
WO2017085235A1 (en) * | 2015-11-19 | 2017-05-26 | Universität Basel | Bacteria-based protein delivery |
WO2023031215A2 (en) * | 2021-09-02 | 2023-03-09 | Umc Utrecht Holding B.V. | Pro-apoptotic construct and use thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020042423A1 (en) * | 1998-04-29 | 2002-04-11 | John R. Richert | Methods for identifying compounds that bind to hla molecules and use of such compounds as hla-agonists or antagonists |
JP2002514430A (ja) * | 1998-05-13 | 2002-05-21 | インサイト・ファーマスーティカルズ・インコーポレイテッド | ヒト・アポトーシス関連タンパク質 |
US6673908B1 (en) * | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
JP2003506071A (ja) * | 1999-05-28 | 2003-02-18 | アポプトシス テクノロジー,アイエヌシー. | アポトーシスを制御する化合物および方法ならびにアポトーシスを制御する化合物を製造およびスクリーニングする方法 |
US20030108539A1 (en) * | 2000-02-14 | 2003-06-12 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US20030077826A1 (en) * | 2001-02-02 | 2003-04-24 | Lena Edelman | Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC) |
AU2002322519A1 (en) * | 2001-07-17 | 2003-03-03 | Incyte Genomics, Inc. | Proteins associated with cell growth, differentiation, and death |
AU2003267124A1 (en) * | 2002-09-09 | 2004-03-29 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
KR100685345B1 (ko) * | 2004-03-27 | 2007-02-22 | 학교법인조선대학교 | 세포사 유도 펩타이드 |
-
2004
- 2004-11-29 EP EP04028278A patent/EP1661912A1/en not_active Withdrawn
-
2005
- 2005-11-18 CN CNA2005800408128A patent/CN101068832A/zh active Pending
- 2005-11-18 EP EP05808463A patent/EP1817334A1/en not_active Withdrawn
- 2005-11-18 CA CA002590512A patent/CA2590512A1/en not_active Abandoned
- 2005-11-18 JP JP2007541802A patent/JP2008521759A/ja active Pending
- 2005-11-18 WO PCT/EP2005/012389 patent/WO2006056370A1/en active Application Filing
- 2005-11-18 US US11/720,413 patent/US20080274956A1/en not_active Abandoned
- 2005-11-18 AU AU2005308990A patent/AU2005308990A1/en not_active Abandoned
- 2005-11-18 BR BRPI0516659-4A patent/BRPI0516659A/pt not_active IP Right Cessation
- 2005-11-18 EA EA200700973A patent/EA013469B1/ru not_active IP Right Cessation
- 2005-11-25 AR ARP050104939A patent/AR051512A1/es active IP Right Grant
-
2007
- 2007-04-11 IL IL182460A patent/IL182460A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA200700973A1 (ru) | 2007-12-28 |
EA013469B1 (ru) | 2010-04-30 |
CN101068832A (zh) | 2007-11-07 |
US20080274956A1 (en) | 2008-11-06 |
EP1817334A1 (en) | 2007-08-15 |
BRPI0516659A (pt) | 2008-09-16 |
JP2008521759A (ja) | 2008-06-26 |
AU2005308990A1 (en) | 2006-06-01 |
EP1661912A1 (en) | 2006-05-31 |
CA2590512A1 (en) | 2006-06-01 |
WO2006056370A1 (en) | 2006-06-01 |
IL182460A0 (en) | 2007-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR051512A1 (es) | Proteina de fusion que comprende un dominio bh3 de una proteina "solo bh3" | |
AR038568A1 (es) | Anticuerpos anti-a beta y su uso | |
CO5720212A1 (es) | Composicion de anticuerpo her2 | |
ES2619332T3 (es) | Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma | |
IL195338A (en) | An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use | |
DE602006018856D1 (de) | Neue nutrazeutika-zusammensetzungen | |
HRP20090245T1 (en) | Pyy agonists and uses thereof | |
BR0211623A (pt) | Agentes de contraste alvos multiméricos com base em peptìdeo | |
ECSP088962A (es) | Nuevos herbicidas | |
BRPI0112859B8 (pt) | análogos de somatostatina, composição farmacêutica, bem como uso dos referidos análogos | |
BR0313970A (pt) | Composições pesticidas contendo ácidos dicarboxìlicos | |
ID29621A (id) | ASETILENIK α-AMINO ASAM HIDROKSAMAT SULFONAMIDA BERBASIS ASAM PENGHAMBAT-PENGHAMBAT TACE | |
PT935609E (pt) | Composicoes cristalizaveis que contem um complexo entre o dominio de protease ns3 do virus da hepatite c e ns4a cristais resultantes | |
DE50112802D1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
UY28641A1 (es) | Anticuerpos | |
BRPI0514411B8 (pt) | formulação, e, método de produzir uma formulação | |
BR0316324A (pt) | Polipeptìdeos e conjugados de interferon-alfa | |
WO2002030959A3 (en) | Peptides derived from smac (diablo) and methods of use therefor | |
BRPI0606445A2 (pt) | inibidores de hipersecreÇço de mucina e mÉtodos de uso | |
BR0308860A (pt) | Fator viii modificado | |
DE60233558D1 (de) | Aminosäurezusammensetzungen zur linderung einer fehlfunktion der leber | |
AR031761A1 (es) | Kit de repinotano | |
ATE529445T1 (de) | Biokinetik zur schnellen beseitigung von polypeptiden | |
ES2422081T3 (es) | Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales | |
DE60118935D1 (de) | Dna & protein bindende miniatur proteine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |